Keywords: double-digit, growth, rates, elude, most, blockbuster, firms
Double-digit growth rates elude most blockbuster firms, says Datmonitor
Article | 27 May 2002
Of the 19 pharmaceutical companies that currently market blockbusterdrugs (ie products with annual global sales of $1 billion or more), only four ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Neovacs moving forward in rheumatoid arthritis, say analysts
